EZH2 and triple-negative breast carcinoma: In 2019, Yu et al36 identified an EZH2 (enhancer of zeste homolog 2)-tri-methylation of histone 3 at lysine 27 (H3K27me3)-TET1 module, showing that EZH2 suppression of TET1 impedes the anti-tumor p53 pathway, impacting survival rates in triple-negative breast cancer patients.